Analysts See $-0.21 EPS for IRIDEX Corporation (IRIX)

February 15, 2018 - By Nellie Frank

 Analysts See $ 0.21 EPS for IRIDEX Corporation (IRIX)
Investors sentiment decreased to 0.55 in Q3 2017. Its down 0.04, from 0.59 in 2017Q2. It fall, as 9 investors sold IRIDEX Corporation shares while 13 reduced holdings. 6 funds opened positions while 6 raised stakes. 5.63 million shares or 4.16% more from 5.41 million shares in 2017Q2 were reported.
97,966 are owned by Millennium Mngmt Ltd Liability Co. Bnp Paribas Arbitrage Sa invested in 32 shares. Jpmorgan Chase invested in 2,224 shares. Ingalls And Snyder Ltd Llc holds 0.01% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX) for 25,015 shares. Deutsche Bancshares Ag stated it has 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). 14,048 are held by Commercial Bank Of New York Mellon. Paragon Assoc & Paragon Assoc Ii Joint Venture holds 1.25 million shares or 10% of its portfolio. Osborne Ptnrs Cap Mngmt Ltd Liability Company has invested 0.09% in IRIDEX Corporation (NASDAQ:IRIX). Northern Tru Corporation stated it has 47,692 shares or 0% of all its holdings. Morgan Stanley holds 37,549 shares or 0% of its portfolio. Neuberger Berman Limited Liability owns 0% invested in IRIDEX Corporation (NASDAQ:IRIX) for 15,000 shares. Wells Fargo And Mn invested 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). Finemark Retail Bank Trust reported 0.02% in IRIDEX Corporation (NASDAQ:IRIX). Blackrock stated it has 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). 88,600 are owned by Perkins Capital Mgmt.

Since December 12, 2017, it had 1 insider purchase, and 0 sales for $39,200 activity.

Analysts expect IRIDEX Corporation (NASDAQ:IRIX) to report $-0.21 EPS on March, 14.They anticipate $0.10 EPS change or 90.91 % from last quarter’s $-0.11 EPS. After having $-0.27 EPS previously, IRIDEX Corporation’s analysts see -22.22 % EPS growth. The stock decreased 0.43% or $0.03 during the last trading session, reaching $6.9. About 11,477 shares traded. IRIDEX Corporation (NASDAQ:IRIX) has declined 35.41% since February 15, 2017 and is downtrending. It has underperformed by 52.11% the S&P500.

IRIDEX Corporation (NASDAQ:IRIX) Ratings Coverage

Among 3 analysts covering IRIDEX (NASDAQ:IRIX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. IRIDEX had 4 analyst reports since January 26, 2016 according to SRatingsIntel. Singular Research initiated it with “Buy” rating and $11.50 target in Tuesday, January 26 report. The rating was initiated by Roth Capital with “Buy” on Wednesday, December 21. The rating was initiated by TH Capital on Wednesday, December 21 with “Buy”.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $79.90 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

More news for IRIDEX Corporation (NASDAQ:IRIX) were recently published by:, which released: “Iridex Corp (IRIX) Reports Filing of Patent Infringement Lawsuit Against …” on January 09, 2018.‘s article titled: “IRIDEX’s (IRIX) CEO William Moore on Q3 2017 Results – Earnings Call Transcript” and published on November 03, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.